Glycerol phenylbutyrate (Ravicti®) for the treatment of urea-cycle disorders

Zorginstituut Nederland has carried out an assessment of the medicinal product glycerol phenylbutyrate (Ravicti®) for the treatment of urea-cycle disorders.
The Zorginstituut advises that Ravicti® can be placed in the Medicine Reimbursement System (GVS) on List 1A in cluster 0A16AXAO V with a standard dose of 18.92 g/day, which is the equivalent of 17.2 ml/day Ravicti® 1.1 g/ml.